Zydus Lifesciences Share Price
(ZYDUSLIFE)
₹895.75▲0.48%
as on 02:54PM, 20 Feb 2025
Zydus Lifesciences Performance
Day's Low
Day's High
₹876.2Day's Price Range₹898.552 Week's Low
52 Week's High
₹876.252-Week Price Range₹1,324.3
| Returns % | |
| 1 Month Return | -10.45 % |
| 3 Month Return | -5.57 % |
| 1 Year Return | -0.48 % |
| Market Stats | |
| Previous Close | ₹891.45 |
| Open | ₹895.45 |
| Volume | 29.89L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹89,700.73Cr |
Zydus Lifesciences Key Statistics
P/E Ratio
19.8
PEG Ratio
1.26
Market Cap
₹89,700.73 Cr
P/B Ratio
6.43
EPS
38.31
Dividend Yield
0.3
Sector
Pharmaceuticals
ROE
23.45
Zydus Lifesciences Mutual Fund Holdings
Zydus Lifesciences Analyst Rating
based on 31 analysts
48.39%
Buy
29.03%
Hold
22.58%
Sell
Based on 31 analysts offering long term price targets for Zydus Lifesciences. An average target of ₹1069.68
Source: S&P Global Market Intelligence
Zydus Lifesciences Share analysis
Zydus Lifesciences price forecast by 31 analysts
Upside of19.99%
High
₹1365
Target
₹1069.68
Low
₹839
Zydus Lifesciences target price ₹1069.68, a slight upside of 19.99% compared to current price of ₹895.75. According to 31 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Zydus Lifesciences revenue growth forecast
Expected growth rate Q1, FY2027:31.24%
Forecast
Actual
Including amortisation and stock based compensations
Zydus Lifesciences EPS growth forecast
EPS estimate Q1, FY2027:16.29%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Zydus Lifesciences Ltd
Zydus Lifesciences Reports Strong Earnings and FDA Approval - 17 Feb, 2025
Zydus Lifesciences announced impressive Q3 FY25 results with a 29.62% increase in net profit and a nearly 3% stock surge following a favorable US FDA inspection outcome.Zydus Lifesciences Reports Strong Growth and Partnerships - 14 Feb, 2025
Zydus Lifesciences achieved significant milestones on February 14, 2025, including successful USFDA inspections, a partnership for a cancer drug, and impressive financial results with a 30% profit increase.Zydus Lifesciences Partners with Synthon for Oncology Product - 12 Feb, 2025
Zydus Lifesciences has entered an exclusive agreement with Synthon BV for a novel oncology product, expected to be filed in 2026. This collaboration aims to address unmet needs in cancer treatment, enhancing patient compliance and flexibility in dosing.Zydus Lifesciences Receives Buy Call Amid Growth Prospects - 11 Feb, 2025
Zydus Lifesciences, trading at Rs 952.95, saw a 1.19% decline. KRChoksey initiated a Buy call with a target of Rs 1201, citing growth from five new US product launches and in-line Q3 results.Zydus Lifesciences Reports Strong Growth Despite Stock Decline - 08 Feb, 2025
Zydus Lifesciences shares fell 1.85% despite strong EBITDA growth guidance of 23% for FY26. Revenue grew 17.2% YoY, with net profit up 29.6%. The company anticipates high single-digit growth in the U.S. and has a robust pipeline for upcoming launches.Zydus Lifesciences Reports Strong Q3 Performance - 06 Feb, 2025
Zydus Lifesciences shows strong Q3 results with a 30% net profit increase and 17% revenue growth. Brokerages maintain positive outlook with target prices around Rs 1000-1050.Zydus Lifesciences Reports Strong Q3 Financial Results - 05 Feb, 2025
Zydus Lifesciences posted a 30% increase in Q3 profit to ₹1,023.5 crore, with revenue growing 17% to ₹5,269.1 crore, fueled by robust US sales and new product launches.Pankaj Patel Receives Padma Bhushan Honor - 26 Jan, 2025
Pankaj Patel, Chairman of Zydus Lifesciences, has been awarded the Padma Bhushan for his significant contributions to the lifesciences sector, reflecting the company's commitment to affordable healthcare innovation.Zydus Lifesciences Expected to Sustain EPS Growth - 24 Jan, 2025
Analysts predict Zydus Lifesciences and peers like Dr. Reddy's and Cipla can achieve low-double digit EPS growth (11-13%) over the medium term, with potential valuations between 25 and 35 times forward earnings. The generic Revlimid opportunity is highlighted as a significant growth driver for Indian pharma companies.Zydus Receives Orphan Drug Designation for Usnoflast - 22 Jan, 2025
Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast for treating ALS, highlighting the urgent need for effective therapies for this fatal disease.Zydus Life Gains USFDA Approval for Usnoflast Trial - 20 Jan, 2025
Zydus Lifesciences has received USFDA approval to conduct a Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor for ALS patients.
Insights on Zydus Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, 911.2 Cr → 1.02K Cr (in ₹), with an average increase of 11.0% per quarter
- POSITIVE IMPACT
Price Rise
In the last 3 years, ZYDUSLIFE stock has moved up by 140.2%
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ZYDUSLIFE has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 7.52% to 7.53% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 5.30K Cr → 5.32K Cr (in ₹), with an average increase of 0.4% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 74.98% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 59.9% return, outperforming this stock by 60.3%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 6.85% to 6.84% in Dec 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 6.57% to 6.32% in Dec 2024 quarter
Zydus Lifesciences Financials
Index Inclusions
Zydus Lifesciences Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 74.98% | 0.00 | |
| Foreign Institutions | 7.53% | 0.15 | |
| Mutual Funds | 6.32% | ||
| Retail Investors | 6.84% | ||
| Others | 4.34% | 6.30 |
Zydus Lifesciences Key Indicators
Zydus Lifesciences Valuation
Zydus Lifesciences in the last 5 years
Lowest (7.34x)
March 7, 2022
Today (19.80x)
February 19, 2025
Industry (51.87x)
February 19, 2025
Highest (34.62x)
March 26, 2024
Zydus Lifesciences Earnings and Dividends
Zydus Lifesciences Ltd Earnings Results
Zydus Lifesciences Ltd’s net profit jumped 29.62% since last year same period to ₹1,023.50Cr in the Q3 2024-2025. On a quarterly growth basis, Zydus Lifesciences Ltd has generated 12.32% jump in its net profits since last 3-months.
Read More about Earnings ResultsZydus Lifesciences Ltd Dividends May,2024
In the quarter ending March 2024, Zydus Lifesciences Ltd has declared dividend of ₹3 - translating a dividend yield of 1.01%.
Read More about Dividends
Zydus Lifesciences Technicals Summary
Bearish
Neutral
Bullish
Zydus Lifesciences Ltd is currently in a Bearish trading position according to technical analysis indicators.
Zydus Lifesciences Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹89,700.73 Cr | 43.85% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹12,048.61 Cr | -5.69% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹66,515.75 Cr | 17.86% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹63,157.44 Cr | 18.28% | 0.53 | NA | NA | |
| BUY | ₹42,474.33 Cr | 17.29% | 0.56 | ₹589 Cr | ₹3,453 Cr |
About Zydus Lifesciences
The company has a strong presence in the global market and is known for its high-quality pharmaceutical products. It manufactures a wide range of generic and specialty drugs, including cardiovascular, anti-infective, anti-diabetic, and oncology medicines. Zydus also produces over-the-counter products and nutritional supplements. Some of its top products include Zetia, Atorvastatin, and Metformin.
Zydus Lifesciences Ltd is also known for its popular brands, such as Cadila, Nutralite, and Zydus Wellness. The company has a strong presence in the Indian market, with its products being sold in more than 20,000 stores across the country. It also exports its products to over 100 countries worldwide.
Share Price: ₹895.75 per share as on 20 Feb, 2025 02:54 PM
Market Capitalisation: ₹89,700.73Cr as of today
Revenue: ₹5,123.50Cr as on December 2024 (Q4 24)
Net Profit: ₹1,004.30Cr as on December 2024 (Q4 24)
Listing date: 18 Apr, 2000
Chairperson Name: Pankaj R Patel
| Organisation | Zydus Lifesciences |
| Headquarters | Ahmedabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Zydus Lifesciences Ltd
What is Zydus Lifesciences Ltd price today?
Zydus Lifesciences Ltd share price today stands at ₹895.75, Open: ₹895.45, Previous Close: ₹891.45, High: ₹898.5, Low: ₹876.2, 52 Week High: ₹1324.3, 52 Week Low: ₹876.2.
How to Buy Zydus Lifesciences Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Zydus Lifesciences Ltd shares
Is Zydus Lifesciences Ltd listed on NSE?
Zydus Lifesciences Ltd is listed on NSE
Is Zydus Lifesciences Ltd listed on BSE?
Zydus Lifesciences Ltd is listed on BSE
What are today's High and Low prices of Zydus Lifesciences Ltd?
- Today's highest price of Zydus Lifesciences Ltd is ₹898.5.
- Today's lowest price of Zydus Lifesciences Ltd is ₹876.2.
What are today's traded volumes of Zydus Lifesciences Ltd?
Today's traded volume of Zydus Lifesciences Ltd(ZYDUSLIFE) is 29.89L.
What is today's market capitalisation of Zydus Lifesciences Ltd?
Today's market capitalisation of Zydus Lifesciences Ltd(ZYDUSLIFE) is ₹89700.73Cr.
What is the 52 Week High and Low Range of Zydus Lifesciences Ltd?
How much percentage Zydus Lifesciences Ltd is down from its 52 Week High?
Zydus Lifesciences Ltd (ZYDUSLIFE) share price is ₹895.75. It is down -32.36% from its 52 Week High price of ₹1324.3
How much percentage Zydus Lifesciences Ltd is up from its 52 Week low?
Zydus Lifesciences Ltd (ZYDUSLIFE) share price is ₹895.75. It is up 2.23% from its 52 Week Low price of ₹876.2
What are the historical returns of Zydus Lifesciences Ltd?
What is the PE ratio of Zydus Lifesciences Ltd today?
PE Ratio of Zydus Lifesciences Ltd is 19.8
PE ratio = Zydus Lifesciences Ltd Market price per share / Zydus Lifesciences Ltd Earnings per share